Becaplermin

Summary

Becaplermin (CHEMBL1201556) is an approved protein (ATC A01AD08); indicated across 3 conditions including ulcer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: A01AD08 (+1 more)
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201556
Name	Becaplermin
Type	Protein
Max phase	4
ATC	A01AD08, D03AX06

Also known as: Becaplermin, Becaplermina, Becaplermine, GEM 21S, GEM-21S, Gemesis, Pdgf-2, Pdgf-bb, Pdgfb, Platelet derived growth factor-bb, Regranex, RWJ 60235

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ulcer disease	3	MONDO:0043839	MONDO:0043839

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
Not specified	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00034788	PHASE3	TERMINATED	A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
NCT02236793	PHASE3	COMPLETED	A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer
NCT02845466	PHASE3	UNKNOWN	Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing
NCT01098357	PHASE1/PHASE2	COMPLETED	Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer
NCT00389636	Not specified	UNKNOWN	TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
NCT00518102	Not specified	COMPLETED	The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
NCT01235260	Not specified	COMPLETED	Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).